AlphaMadera's AlphaVal page computes Bristol-Myers Squibb Company's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag BMY as undervalued, fairly valued, or overvalued.

What is Bristol-Myers Squibb Company's fair value?

Fair value for BMY is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value BMY?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from BMY's most recent reported fundamentals.

BMY - Bristol-Myers Squibb Company

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $62.60 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 65% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Undervalued Strong

Trading 50.6% below fair value

Current Price $56.70

Bear Case $75.12 32.5% upside ($75.12 - $56.70) / $56.70 = 32.5% 7% stage 1 growth, 11% discount

Fair Value $114.72 102.3% upside ($114.72 - $56.70) / $56.70 = 102.3% 12% stage 1 growth, 11% discount

Bull Case $155.86 174.9% upside ($155.86 - $56.70) / $56.70 = 174.9% 16% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

12.2%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (12% base case)

Terminal Value % of EV 41%

Implied Market Multiple 12.2x

Market is pricing in (growth) 2.3% vs our 12.2% base

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $62.60 from 41 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $114.72 per share.

Warnings

ℹ Wall Street's average price target is $62.60 (from 41 analysts). Our estimate is 119% above the consensus -- consider that gap carefully.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions